# Junta clínica — PT-pseudo_2b3ef1d3a505 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_2b3ef1d3a505",
  "pid": "PT-pseudo_2b3ef1d3a505",
  "task": 1,
  "psa": 4.2,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.06,
  "psav": 0.66,
  "psap": 3.7,
  "vol": 69.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.81166416,
  "medhx": "COPD",
  "meds": "tiotropium, salbutamol PRN",
  "notes": "PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.",
  "pmhx": [
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "185 cm",
    "bmi": "19.3",
    "bp": "113/72 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "23 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review."
    },
    {
      "s": "History",
      "t": "A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "mechanical engineer",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Pulmonary function test — known COPD follow-up",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "31 units / week (heavy)",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 9/35 (moderate LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.34
  uncertainty  +/- 0.15 (95% CI 0.05-0.64); among patients it cannot tell apart the outcome was 0.93 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using the PI-RADS score to trigger a biopsy, noting that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also mentions that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D $< 0.15$.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" does not account for the fact that the patient has a PI-RADS 5 lesion, which is a high-risk finding according to the guideline. The classifier's bid is blind to the PI-RADS score, a variable the guideline makes decisive for biopsy recommendation.

WHAT WE STILL NEED
The mpMRI prose - the mpMRI prose states the PI-RADS score is 5, which is a high-risk finding, which suggests a biopsy is indicated according to the guideline.
The prior biopsy status - the prior biopsy status is "Positive," which is a known fact that the cohort study indicates that this fact means the panel cannot settle the decision.
The PSA trend - the PSA trend shows a rise from 3.7 to 4.2 ng/mL over two months, which is a variable the guideline makes decisive for risk stratification.
The prostate volume - the prostate volume is 69.0 mL, which is a variable the guideline makes decisive for risk stratification.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS 5 finding, combined with the rising PSA trend and prior positive biopsy, mandates a repeat biopsy according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, specifically regarding the PI-RADS 5 lesion.
  psa_trend (get_psa_trend) -> Confirm the PSA trend data to assess risk stratification.
  previous_notes (get_previous_notes) -> Review the management context, including the prior biopsy result.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding the PI-RADS 5 lesion and its characteristics?
  Q2. How does the PSA trend (from 3.7 to 4.2 ng/mL over two months) factor into the decision according to the guidelines?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states the PI-RADS 5 lesion is in the right mid-peripheral zone, measuring roughly 18 x 15 x 12 mm, and the csPCa predicted probability is 0.81166416.
psa_trend
The PSA trend shows a rise from 3.7 ng/mL to 4.2 ng/mL over two months, with values recorded on "Jun 2023" (0.8), "Dec 2023" (2.2), "Jul 2024" (0.7), and "Jan 2025" (4.2).
previous_notes
The previous notes indicate that a December 2023 reading of 3.0 ng/mL triggered a follow-up test, and an initial measurement of 2.5 ng/mL sparked a differential between benign enlargement and early malignancy.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for them in the plan, and the key variables for the decision were covered by the other requested documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a PI-RADS 5 lesion, which is a high-risk finding according to the EAU guideline.
The PSA trend shows a rise from 3.7 ng/mL to 4.2 ng/mL over two months, which is a variable the guideline makes decisive for risk stratification.
AGAINST sampling this patient now
The prior biopsy status is "Positive," which the cohort study indicates means the panel cannot settle the decision.

WHERE THIS LEANS
The combination of a PI-RADS 5 finding and a rising PSA trend strongly suggests a need for further investigation, despite the prior positive biopsy complicating the interpretation.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened have answered Q1 and Q2. The radiology report states the PI-RADS 5 lesion is in the right mid-peripheral zone, measuring 18 x 15 x 12 mm, with a csPCa predicted probability of 0.81166416. The PSA trend confirms a rise from 3.7 to 4.2 ng/mL over two months, which is a variable the guideline makes decisive for risk stratification.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the Expert-EAU's concern that the PI-RADS 5 finding suggests a biopsy is indicated, which contradicts the Expert-Classifier's suggestion of "NO BIOPSY" by highlighting the PI-RADS score as a decisive variable.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding the PI-RADS 5 lesion and its characteristics? Answered by the Registrar via the radiology_report, stating the lesion is in the right mid-peripheral zone, measuring 18 x 15 x 12 mm, and has a csPCa predicted probability of 0.81166416.
Q2. How does the PSA trend (from 3.7 to 4.2 ng/mL over two months) factor into the decision according to the guidelines? Answered by the Registrar via the psa_trend, confirming the rise is a variable the guideline makes decisive for risk stratification.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS 5 finding because the guideline uses this score to trigger biopsy, and the PSA trend because the guideline makes this rise a decisive variable for risk stratification. The prior positive biopsy is a variable the cohort study indicates means the panel cannot settle the decision, which the guideline does not explicitly support as a deciding factor here.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy based on the strong indication from the PI-RADS 5 finding and the rising PSA trend, despite the complicating factor of the prior positive biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the prior biopsy status was 'Positive', which the cohort study indicates means the panel cannot settle the decision. This conclusion is supported by the Expert-Classifier's suggestion of no biopsy, which was weighted by the 'Positive' prior biopsy status. The known prior diagnosis provides sufficient characterization for management, making further tissue sampling unnecessary at this time.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
